Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1 在健康受试者中评价LBG-1600M片单次给药的安全性、耐受性、药代动力学临床研究
[Translation] A clinical study to evaluate the safety, tolerability and pharmacokinetics of a single dose of LBG-1600M tablets in healthy subjects
主要目的:评估健康成人空腹条件下单次服用LBG-1600M片后的安全性和耐受性。
次要目的:1)评估健康成人空腹条件下单次服用LBG-1600M片后的药代动力学及药效学特性;2)初步评估健康成人空腹条件下单次服用LBG-1600M片后的物质平衡。
[Translation] Primary objective: To evaluate the safety and tolerability of a single dose of LBG-1600M tablets in healthy adults on an empty stomach.
Secondary objectives: 1) To evaluate the pharmacokinetic and pharmacodynamic properties of a single dose of LBG-1600M tablets in healthy adults on an empty stomach; 2) To preliminarily evaluate the material balance of a single dose of LBG-1600M tablets in healthy adults on an empty stomach.
100 Clinical Results associated with Suzhou Longbotai Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Suzhou Longbotai Pharmaceutical Co., Ltd.
100 Deals associated with Suzhou Longbotai Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Suzhou Longbotai Pharmaceutical Co., Ltd.